Transcelerate teams to take on investigator selection bias

By Gareth Macdonald contact

- Last updated on GMT

Transcelerate teams with DrugDev
Transcelerate teams with DrugDev

Related tags: Pharmacology, Clinical trial

A register of clinical investigators can help eliminate bias according to Big Pharma Group Transcelerate, which has teamed with DrugDev to develop such a database.

Transcelerate announced it had partnered to develop Investigator Registry (IR) this week, explaining that member companies will pool data on the staff that run trials which will be stored in a database hosted by DrugDev.

The idea is to allow Transcelerate's member companies to select clinical trial investigators based on their past performance and expertise according to a spokeswoman for the industry group.

She told Outsourcing-pharma.com that: “Today, investigator selection is largely based on previous study experience and local site relationships.

The IR attempts to broaden the process by providing clinical operations professionals with the integrated data they need to make smart site selection decisions, and by ensuring that sites have direct access to appropriate trial opportunities."

She added that: “As the IR is adopted by more and more participating TransCelerate member companies, our vision is that the investigator selection bias that exists today will eventually be replaced by a more evidence-driven process​.”

Each investigator stored in the database will be assigned a “golden number” that links details of that person’s experience to data stored in Transcelerate’s existing Shared Investigator Platform (SIP).

The spokeswoman said: “Examples of data fields to be included in the registry: person contact information, TransCelerate CV, facility contact information, TransCelerate site profile form, protocol information, and historical study metrics.​”

She added that: “For pharmaceutical companies, the ability to expeditiously find investigator matches for their trials will drive improved performance – including faster study start-up, faster patient recruitment, increased patient retention, enhanced operational efficiencies, and fewer non-performing or under-performing sites.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars